What are the effects and effects of Vandetanib?

The research and development idea of Vandetanib is to block multiple signaling pathways that tumor cells rely on to survive and spread. Therefore, it is not a drug that only acts on a single target in the traditional sense, but a multi-target inhibitor. Specifically, it can simultaneously inhibit vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and RET tyrosine kinase. By inhibiting VEGFR signaling, drugs can effectively block the formation of new blood vessels in tumors and reduce blood supply to tumors, thereby delaying their growth; by inhibiting EGFR, they can inhibit the proliferation and survival of tumor cells; and the inhibitory effect on RET mutations is particularly critical for RET-related tumors such as medullary thyroid cancer.

In clinical application, the main role of vandetanib is focused on the treatment of medullary thyroid cancer (MTC; thyroid cancer). MTC is a rare malignant tumor originating from thyroid parafollicular cells. It has limited response to traditional chemotherapy and radiotherapy. Therefore, targeted drugs have become an important breakthrough in treatment. Overseas studies have shown that vandetanib has good effects in delaying disease progression, reducing tumor size and improving patients' quality of life. In addition, due to its multi-target mechanism, it has also been explored for its potential role in some non-small cell lung cancer (NSCLC), glioma and other tumor types, although no standard indications have been formed yet.

It is worth noting that vandetanib not only inhibits tumor growth, but also improves symptoms. For example, for MTC patients with tumor-related diarrhea and pain, drug treatment can significantly improve clinical performance. This is also an important manifestation of its value.

Of course, the effects of drugs are accompanied by the risk of adverse reactions. Common side effects include rash, diarrhea, fatigue, QT interval prolongation, etc. These require close monitoring and individualized adjustments by clinicians during use.

Reference materials:https://www.drugs.com/caprelsa.html